Skip to main content
. Author manuscript; available in PMC: 2018 Sep 5.
Published in final edited form as: AME Med J. 2018 Jun 13;3:66. doi: 10.21037/amj.2018.06.02

Figure 1.

Figure 1

A potential bypassing pathway by glucocorticoid receptor (GR) upregulation leading to antiandrogen resistance. Blockade of androgen receptor (AR) by enzalutamide or abiraterone can lead to elevated GR expression which activates a subset of AR target genes as well as GR target genes causing tumor growth (red arrows). Combination with GR antagonist may overcome GR-driven resistance to antiandrogens.